- Home
- SM vs HCM Comparison
SM vs HCM Comparison
Compare SM & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SM | HCM |
|---|---|---|
| Founded | 1908 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | SM | HCM |
|---|---|---|
| Price | $20.13 | $14.15 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $37.25 | $13.75 |
| AVG Volume (30 Days) | ★ 3.0M | 28.1K |
| Earning Date | 11-03-2025 | 08-07-2025 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.33 | 0.53 |
| Revenue | ★ $3,166,673,000.00 | $602,197,000.00 |
| Revenue This Year | $32.15 | N/A |
| Revenue Next Year | $35.63 | $15.54 |
| P/E Ratio | ★ $3.18 | $5.22 |
| Revenue Growth | ★ 35.48 | N/A |
| 52 Week Low | $17.58 | $11.51 |
| 52 Week High | $44.95 | $19.50 |
Technical Indicators
Market Signals| Indicator | SM | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 37.36 |
| Support Level | $17.71 | $14.11 |
| Resistance Level | $19.80 | $14.63 |
| Average True Range (ATR) | 0.79 | 0.26 |
| MACD | 0.37 | -0.00 |
| Stochastic Oscillator | 77.49 | 26.31 |
Price Performance
Historical ComparisonAbout SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.